Cosmo Pharmaceuticals N.V.

DB:C43 Stock Report

Market Cap: €933.8m

Cosmo Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Giovanni Di Napoli

Chief executive officer

€4.0m

Total compensation

CEO salary percentage0.7%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Giovanni Di Napoli's remuneration changed compared to Cosmo Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024€4m€27k

€133m

Compensation vs Market: Giovanni's total compensation ($USD4.32M) is above average for companies of similar size in the German market ($USD1.42M).

Compensation vs Earnings: Insufficient data to compare Giovanni's compensation with company performance.

CEO

Giovanni Di Napoli (50 yo)

less than a year

Tenure

€3,995,280

Compensation

Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...

Leadership Team

NamePositionTenureCompensationOwnership
Alessandro Della Cha
Non Executive Chairman19.3yrs€1.77mno data
Giovanni Di Napoli
CEO & Directorless than a year€4.00mno data
Mauro Ajani
Founder & Non-Executive Director19.3yrs€2.64mno data
Niall Donnelly
Executive VP of Corporate Governanceless than a year€690.01kno data
Svetlana Sigalova
Chief Financial Officerless than a yearno datano data
Marco Lecchi
Chief Operating Officer4.3yrsno datano data
Davide Malavasi
Qualified Person & Technical Director13.6yrsno datano data
Luigi Longo
Chief Scientific Officer3yrsno datano data
Hazel Winchester
Head of Investor Relations3.3yrsno datano data
Roberto Villa
Chief Manufacturing Officer28.3yrsno datano data
Ngo Nhan
President of Cosmo Intelligent Medical Devicesno datano datano data
Andrea Cherubini
Chief AI Officer5.3yrsno datano data

3.3yrs

Average Tenure

51.5yo

Average Age

Experienced Management: C43's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alessandro Della Cha
Non Executive Chairman19.3yrs€1.77mno data
Giovanni Di Napoli
CEO & Directorless than a year€4.00mno data
Mauro Ajani
Founder & Non-Executive Director19.3yrs€2.64mno data
Niall Donnelly
Executive VP of Corporate Governanceless than a year€690.01kno data
William Sandborn
Member of Scientific Advisory Boardno datano datano data
Geert D'Haens
Member of Scientific Advisory Boardno datano datano data
Silvio Danese
Member of Scientific Advisory Boardno datano datano data
Maria Roncarolo
Non-Executive Director13yrs€131.45kno data
Ralf Kiesslich
Member of Scientific Advisory Boardno datano datano data
Robert Steffen
Member of Scientific Advisory Boardno datano datano data
Silvana Perretta
Non-Executive Directorless than a year€131.58kno data
John O'Dea
Non-Executive Directorless than a year€131.58kno data

0.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: C43's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/01 22:50
End of Day Share Price 2025/04/01 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Silvia SchanzBank Vontobel AG
Laura HindleyBerenberg